alexa From Discovery To Preclinical Study Of N-Rephasin® SAL200: A Novel Antibacterial Drug For Multidrugresistant Staphylococci-associated Infections | 69851
ISSN: 2157-7609

Journal of Drug Metabolism & Toxicology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd World Congress and Exhibition on Antibiotics and Antibiotic Resistance
July 31-August 01, 2017 | Milan, Italy

Myung-Soo Kang, Jun S Y, Gi-Mo Jung, Yoon S J, Kim J W and Kang S H
iNtRON Biotechnology, Korea
ScientificTracks Abstracts: J Drug Metab Toxicol
DOI: 10.4172/2157-7609-C1-008
Abstract
Statement of the Problem: Emergence and dispersal of multidrug-resistant Staphylococcus aureus (SA) (MRSA) are rapid and wide, necessitating an invention of novel class of MRSA-controlling effective antimicrobial drug that is not likely to induce a resistance. This presentation describes our 15 year-long experience in development of a bacteriophage-derived endolysin as promising new antibiotics. Materials & Method: A bacteriophage SAP-1 specifically infecting SA was isolated from sewage water. Whole genome sequencing revealed typical genomic structure of lytic bacteriophage and identified putative peptidoglycan (PG) hydrolase gene encoding SAL-1 endolysin. The wild type SAL-1 with no extraneous amino acids was highly purified in compliance to a Good Manufacturing Practice (GMP) standard and further formulated to N-Rephasin® SAL200. Findings: SAL200 showed to have unique modes of action: It potently and specifically killed planktonic and encapsulated SA as well as biofilm-producing SA cells, but not for other species. SAL200 exhibited strong bactericidal activity against more than 425 clinical isolates including 1 vancomycin-intermediate SA and 336 methicillin-resistant SA isolates. It directly bound to and lysed SA as quickly as within ten minutes and apparently did not induce an emergence of any resistant SA strains from 30-times repeated exposure at sub-lethal concentrations. Intravenous injection of SAL200 significantly prolonged survival of mice and reduced viable bacterial counts in MRSA infection mouse model. Further safety evaluation studies for rodents, dogs and monkeys showed neither death nor severe adverse events. Any abnormal findings-if any- were tolerable and transient. Conclusion: The SAL200 specifically lysed SA strains including antibiotic-resistant SA strains in vitro and in vivo with excellent in vivo safety.
Biography

Myung-Soo Kang has earned his BS to PhD degrees from Department of Biology at Seoul National University, Korea. After his PhD, he did his Postdoctoral Research Fellowship at Department of Microbiology and Molecular Genetics, Harvard Medical School/Brigham and Women’s Hospital. He then joined as a Professor and Faculty at Samsung Medical Center, Center for Future Medicine. Since 2016, he has been a Chief Scientist and Vice Director of Institute of iNtRON Biotechnology. He is interested in development of bacteriophages and phage –derived bio drugs for effectively controlling bacterial infections.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version